Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.
Yang Mao-DraayerJeffrey A CohenAmit Bar-OrMay H HanBarry SingerIan M WilliamsXiangyi MengChelsea ElamJamie L WeissGina Mavrikis CoxMarina ZiehnBruce Anthony Campbell Creenull nullPublished in: Multiple sclerosis journal - experimental, translational and clinical (2022)
FLUENT provides insights into the utility of immunological profiling to evaluate therapy response and potential infection risk.